<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=13104&amp;modal=1&amp;valnames=arms&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="291793" class="table-">
                
                <td>Feb. 11, 2022, 8 a.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Investigational ProductRecombinant covid-19 vaccine (ChAdOx1 nCoV-19) Fiocruz/AstraZenecaDose: 0.5 mL; containing 5 \u00d7 1010 viral particlesVia: Intramuscular (deltoid)Covid-19 Pfizer/Wyeth Vaccine (ComirnatyTM)Dose: 0.3ml; containing 30mcg mRNAVia: Intramuscular (deltoid)Janssen recombinant covid-19 vaccineDose: 0.5mlRoute: intramuscular (deltoid)The volunteers will be grouped into three cohorts; (Cohorts 1; 2 and 3) according to the vaccines received in the primary two-dose vaccine schedule offered in the vaccination campaigns against COVID-19. The cohorts will then be divided into two groups; each receiving a booster dose with different vaccines; which may be a homologous or heterologous booster.Cohort 1: Primary shedule with two doses of Coronavac/ButantanIntervention (booster vaccine):Group 1.1 - Pfizer vaccineGroup 1.2 - Fiocruz/AstraZeneca VaccineGroup 1.3 - Janssen VaccineCohort 2: Primary schedule with two doses of Fiocruz/AstraZenecaIntervention (booster vaccine):Group 2.1 - Pfizer vaccineGroup 2.2 - Fiocruz/AstraZeneca VaccineGroup 2.3 - Janssen VaccineCohort 3: Primary shedule with two doses of Pfizer vaccineIntervention (booster vaccine):Group 3.1 - Pfizer VaccineGroup 3.2 - Fiocruz/AstraZeneca VaccineGroup 3.3 - Janssen VaccineThe number of participants in each of the cohorts is 3000. Totaling 9000 volunteers.For the immunogenicity sub-study; 400 volunteers will be selected in each intervention group.Visit 1Inclusion and exclusion criteria; informed consent; randomization; clinical history; epidemiological data; vaccination. Blood collection for serology in volunteers included in the immunogenicity substudy.Visit 2As;D014614;D022223;D015164&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;5 \u00d7 10^10/0.5mL;1;IM;prior received Coronavac&quot;, &quot;treatment_id&quot;: 161, &quot;treatment_name&quot;: &quot;Chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;30mcg/0.3mL;1;IM;prior received Coronavac&quot;, &quot;treatment_id&quot;: 222, &quot;treatment_name&quot;: &quot;Bnt162b2&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;5 \u00d7 10^10/0.5mL;1;IM;prior received Chadox1 ncov-19&quot;, &quot;treatment_id&quot;: 161, &quot;treatment_name&quot;: &quot;Chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;30mcg/0.3mL;1;IM;prior received Chadox1 ncov-19&quot;, &quot;treatment_id&quot;: 222, &quot;treatment_name&quot;: &quot;Bnt162b2&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;5 \u00d7 10^10/0.5mL;1;IM;prior received Bnt162b2&quot;, &quot;treatment_id&quot;: 161, &quot;treatment_name&quot;: &quot;Chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;30mcg/0.3mL;1;IM;prior received Bnt162b2&quot;, &quot;treatment_id&quot;: 222, &quot;treatment_name&quot;: &quot;Bnt162b2&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="290150" class="table-">
                
                <td>Jan. 13, 2022, 11 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Investigational ProductRecombinant covid-19 vaccine (ChAdOx1 nCoV-19) Fiocruz/AstraZenecaDose: 0.5 mL; containing 5 \u00d7 1010 viral particlesVia: Intramuscular (deltoid)Covid-19 Pfizer/Wyeth Vaccine (ComirnatyTM)Dose: 0.3ml; containing 30mcg mRNAVia: Intramuscular (deltoid)The volunteers will be grouped into three cohorts; (Cohorts 1; 2 and 3) according to the vaccines received in the primary two-dose vaccine schedule offered in the vaccination campaigns against COVID-19. The cohorts will then be divided into two groups; each receiving a booster dose with different vaccines; which may be a homologous or heterologous booster.Cohort 1: Primary shedule with two doses of Coronavac/ButantanIntervention (booster vaccine):Group 1.1 - Pfizer vaccineGroup 1.2 - Fiocruz/AstraZeneca VaccineCohort 2: Primary schedule with two doses of Fiocruz/AstraZenecaIntervention (booster vaccine):Group 2.1 - Pfizer vaccineGroup 2.2 - Fiocruz/AstraZeneca VaccineCohort 3: Primary shedule with two doses of Pfizer vaccineIntervention (booster vaccine):Group 3.1 - Pfizer VaccineGroup 3.2 - Fiocruz/AstraZeneca VaccineThe number of participants in each of the cohorts is 3000. Totaling 9000 volunteers.For the immunogenicity substudy; 500 volunteers will be selected from each of the six study groups.Visit 1Inclusion and exclusion criteria; informed consent; randomization; clinical history; epidemiological data; vaccination. Blood collection for serology in volunteers included in the immunogenicity substudy.Visit 2Assessment of solicited and unsolicited adverse events; with participant diary review. Blood collection for serology in volunteers included in the immunogenicity substudy.Visit 3;D014614;D022223;D015164&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
Feb. 11, 2022, 8 a.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Investigational ProductRecombinant covid-19 vaccine (ChAdOx1 nCoV-19) Fiocruz/AstraZenecaDose: 0.5 mL; containing 5 \u00d7 1010 viral particlesVia: Intramuscular (deltoid)Covid-19 Pfizer/Wyeth Vaccine (ComirnatyTM)Dose: 0.3ml; containing 30mcg mRNAVia: Intramuscular (deltoid)Janssen recombinant covid-19 vaccineDose: 0.5mlRoute: intramuscular (deltoid)The volunteers will be grouped into three cohorts; (Cohorts 1; 2 and 3) according to the vaccines received in the primary two-dose vaccine schedule offered in the vaccination campaigns against COVID-19. The cohorts will then be divided into two groups; each receiving a booster dose with different vaccines; which may be a homologous or heterologous booster.Cohort 1: Primary shedule with two doses of Coronavac/ButantanIntervention (booster vaccine):Group 1.1 - Pfizer vaccineGroup 1.2 - Fiocruz/AstraZeneca VaccineGroup 1.3 - Janssen VaccineCohort 2: Primary schedule with two doses of Fiocruz/AstraZenecaIntervention (booster vaccine):Group 2.1 - Pfizer vaccineGroup 2.2 - Fiocruz/AstraZeneca VaccineGroup 2.3 - Janssen VaccineCohort 3: Primary shedule with two doses of Pfizer vaccineIntervention (booster vaccine):Group 3.1 - Pfizer VaccineGroup 3.2 - Fiocruz/AstraZeneca VaccineGroup 3.3 - Janssen VaccineThe number of participants in each of the cohorts is 3000. Totaling 9000 volunteers.For the immunogenicity sub-study; 400 volunteers will be selected in each intervention group.Visit 1Inclusion and exclusion criteria; informed consent; randomization; clinical history; epidemiological data; vaccination. Blood collection for serology in volunteers included in the immunogenicity substudy.Visit 2As;D014614;D022223;D015164", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "5 \u00d7 10^10/0.5mL;1;IM;prior received Coronavac", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "30mcg/0.3mL;1;IM;prior received Coronavac", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "5 \u00d7 10^10/0.5mL;1;IM;prior received Chadox1 ncov-19", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "30mcg/0.3mL;1;IM;prior received Chadox1 ncov-19", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "5 \u00d7 10^10/0.5mL;1;IM;prior received Bnt162b2", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "30mcg/0.3mL;1;IM;prior received Bnt162b2", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}]
Jan. 13, 2022, 11 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Investigational ProductRecombinant covid-19 vaccine (ChAdOx1 nCoV-19) Fiocruz/AstraZenecaDose: 0.5 mL; containing 5 \u00d7 1010 viral particlesVia: Intramuscular (deltoid)Covid-19 Pfizer/Wyeth Vaccine (ComirnatyTM)Dose: 0.3ml; containing 30mcg mRNAVia: Intramuscular (deltoid)The volunteers will be grouped into three cohorts; (Cohorts 1; 2 and 3) according to the vaccines received in the primary two-dose vaccine schedule offered in the vaccination campaigns against COVID-19. The cohorts will then be divided into two groups; each receiving a booster dose with different vaccines; which may be a homologous or heterologous booster.Cohort 1: Primary shedule with two doses of Coronavac/ButantanIntervention (booster vaccine):Group 1.1 - Pfizer vaccineGroup 1.2 - Fiocruz/AstraZeneca VaccineCohort 2: Primary schedule with two doses of Fiocruz/AstraZenecaIntervention (booster vaccine):Group 2.1 - Pfizer vaccineGroup 2.2 - Fiocruz/AstraZeneca VaccineCohort 3: Primary shedule with two doses of Pfizer vaccineIntervention (booster vaccine):Group 3.1 - Pfizer VaccineGroup 3.2 - Fiocruz/AstraZeneca VaccineThe number of participants in each of the cohorts is 3000. Totaling 9000 volunteers.For the immunogenicity substudy; 500 volunteers will be selected from each of the six study groups.Visit 1Inclusion and exclusion criteria; informed consent; randomization; clinical history; epidemiological data; vaccination. Blood collection for serology in volunteers included in the immunogenicity substudy.Visit 2Assessment of solicited and unsolicited adverse events; with participant diary review. Blood collection for serology in volunteers included in the immunogenicity substudy.Visit 3;D014614;D022223;D015164", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]